Dr. Reddy’s Laboratories Ltd ADR Market Cap ($11.16 Billion)
Market Cap & Net Worth: Dr. Reddy’s Laboratories Ltd ADR (RDY)
Dr. Reddy’s Laboratories Ltd ADR market cap. Dr. Reddy’s Laboratories Ltd ADR (NYSE:RDY) has a market capitalization of $11.16 Billion ($11.16 Billion) as of November 1, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #1993 globally and #757 in its home market, demonstrating a 4.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dr. Reddy’s Laboratories Ltd ADR's stock price $13.58 by its total outstanding shares 832532930 (832.53 Million). Also see Dr. Reddy’s Laboratories Ltd ADR cash flow conversion for how efficiently the company converts equity into cash flow.
Dr. Reddy’s Laboratories Ltd ADR Market Cap History (2015–2026)
Dr. Reddy’s Laboratories Ltd ADR market cap history from 2015 to 2026. Data shows growth from $6.26 Billion to $11.80 Billion (2.02% CAGR). Check Dr. Reddy’s Laboratories Ltd ADR stock price for real-time trading data and today's change.
Index Memberships
Dr. Reddy’s Laboratories Ltd ADR is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.45 Trillion | 0.32% | #15 of 24 |
Weight: Dr. Reddy’s Laboratories Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dr. Reddy’s Laboratories Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dr. Reddy’s Laboratories Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Dr. Reddy’s Laboratories Ltd ADR growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.04x
Dr. Reddy’s Laboratories Ltd ADR's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.21x
Dr. Reddy’s Laboratories Ltd ADR's market cap is 0.21 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.30 Billion | $154.71 Billion | $20.01 Billion | 0.04x | 0.31x |
| 2017 | $5.26 Billion | $140.81 Billion | $12.04 Billion | 0.04x | 0.44x |
| 2018 | $5.33 Billion | $142.03 Billion | $9.81 Billion | 0.04x | 0.54x |
| 2019 | $5.78 Billion | $153.85 Billion | $18.80 Billion | 0.04x | 0.31x |
| 2020 | $10.48 Billion | $174.60 Billion | $19.50 Billion | 0.06x | 0.54x |
| 2021 | $9.66 Billion | $2.56 Billion | $232.21 Million | 3.78x | 41.62x |
| 2022 | $7.99 Billion | $214.39 Billion | $23.57 Billion | 0.04x | 0.34x |
| 2023 | $10.91 Billion | $245.88 Billion | $45.07 Billion | 0.04x | 0.24x |
| 2024 | $13.15 Billion | $279.16 Billion | $55.68 Billion | 0.05x | 0.24x |
| 2025 | $11.69 Billion | $325.54 Billion | $56.54 Billion | 0.04x | 0.21x |
Competitor Companies of RDY by Market Capitalization
Companies near Dr. Reddy’s Laboratories Ltd ADR in the global market cap rankings as of November 1, 2026. Also see Dr. Reddy’s Laboratories Ltd ADR assets under control for a full breakdown of the balance sheet.
Key companies related to Dr. Reddy’s Laboratories Ltd ADR by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Dr. Reddy’s Laboratories Ltd ADR (2015–2026)
Market capitalization of Dr. Reddy’s Laboratories Ltd ADR from 2015 to today. Between 2015 and today, Dr. Reddy’s Laboratories Ltd ADR's market cap moved from $6.26 Billion to $ 11.80 Billion, with a yearly change of 2.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.80 Billion | +0.93% |
| 2025 | $11.69 Billion | -11.08% |
| 2024 | $13.15 Billion | +20.51% |
| 2023 | $10.91 Billion | +36.48% |
| 2022 | $7.99 Billion | -17.29% |
| 2021 | $9.66 Billion | -7.83% |
| 2020 | $10.48 Billion | +81.45% |
| 2019 | $5.78 Billion | +8.45% |
| 2018 | $5.33 Billion | +1.26% |
| 2017 | $5.26 Billion | -16.43% |
| 2016 | $6.30 Billion | +0.61% |
| 2015 | $6.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Dr. Reddy’s Laboratories Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.16 Billion USD |
| MoneyControl | $11.16 Billion USD |
| MarketWatch | $11.16 Billion USD |
| marketcap.company | $11.16 Billion USD |
| Reuters | $11.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more